20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Exploring the Potential of Depreotide in Diagnosing Metastatic Lung Disease

NINGBO INNO PHARMCHEM CO.,LTD. is committed to advancing diagnostic capabilities in healthcare. This involves the development and supply of specialized chemical agents that enable more accurate and timely disease identification. Depreotide is one such agent, offering significant advantages in the diagnosis of metastatic lung disease.

Metastasis, the spread of cancer from its primary site to other parts of the body, is a critical factor in cancer prognosis and treatment. The lungs are a common site for metastases from various cancers. Depreotide, a peptide analog for lung nodules, is particularly useful in this context due to its affinity for somatostatin receptors, which are often present on metastatic cancer cells. Its ability to act as a somatostatin receptor imaging agent allows for the visualization of these secondary tumors within the lung parenchyma.

A notable application of Depreotide is in the renal cell carcinoma lung metastasis detection. Renal cell carcinoma, originating in the kidneys, has a propensity to spread to the lungs. Identifying these metastases accurately is crucial for determining the stage of the disease and selecting appropriate treatment strategies, which may include surgery or targeted therapies. Depreotide's role in this specific scenario underscores its value as a diagnostic tool.

The broader utility of Depreotide lies in its contribution to non-invasive cancer imaging. By providing clear visual evidence of disease presence and extent, it can help clinicians make informed decisions without the immediate need for invasive procedures. This not only improves patient comfort but also expedites the diagnostic process. The ability to perform precise malignant vs benign nodule assessment using Depreotide further enhances its diagnostic power.

In essence, Depreotide represents a significant stride in diagnostic nuclear medicine. Its targeted approach, focusing on specific biological markers, allows for a more refined understanding of cancer spread and characteristics. NINGBO INNO PHARMCHEM CO.,LTD. is proud to support the medical community with such advanced diagnostic solutions, contributing to better patient outcomes through early and accurate detection.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Advancements in Cancer Detection: The Role of Depreotide in Targeting Somatostatin Receptors

Next: The Precision of Depreotide: A Guide to Somatostatin Receptor Imaging in Oncology

All Rights Reserved